ROBOSENSE
9.2.2021 20:02:05 CET | Business Wire | Press release
RoboSense LiDAR (https://robosense.ai/ ) today released the latest version of the ground truth data system and evaluation tool chain RS-Reference 2.1, used for LiDARs and multi-sensor fusion systems performance evaluation. The original RS-Reference version was launched in the market in 2016, when the automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 project was established. Used by global OEMs and Tier1s, the system has been continuously improved and upgraded with more efficient and useful evaluation function modules and software tool chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210209005689/en/
While the evaluation function modules can be liked to an exam, the ground truth data is the "answer" for the evaluation of the perception system. Therefore, the accuracy of ground truth data must be significantly higher than the device under test (DuT) in all aspects including detection performance and geometric error.
The ground truth data, usually stored in the PB-Level, includes dynamic information such as obstacle types, speeds, and locations, and static information such as lane lines and road boundaries.
Data labeling quality and data generation efficiency are the key factors to ground truth data.
- The RS-Reference system provides a set of ground truth data generation and evaluation solutions, and outputs detection performance and geometric error indicators with a labeling efficiency close to 1:1. This is significantly more accurate than real-time perception, manual labeling and traditional labeling tools.
- High performance and mature sensor data collection system: the RS-Reference system contains the RoboSense 128-beam LiDAR RS-Ruby, Leopard camera, Continental 408 millimeter-wave radar, GI-6695 RTK, and two added RoboSense RS-Bpearl LiDAR for near-field blind spots in the 2.1 version.
- Detached roof-mounted deployment without vehicle body modification: the RS-Reference system adapts to different vehicle sizes, does not occupy the sensor installation position of the DuTs, and directly evaluates the intelligent driving system that is consistent with the sensor sets of commercial vehicles.
- Vastly improved/accumulated perception algorithm and offline processing mechanism: The algorithm is key to smart labeling instead of manual labeling, and is responsible for the extraction of ground truth data. The RS-Reference system uses a customized and dedicated offline perception algorithm, which is the product of RoboSense’s 13+ years’ of accumulated experience of LiDAR sensing algorithm technology. It performs a “full life process tracking and identification" for each obstacle data, and extracts all ground truth data from each frame. The RS-Reference system can pick up speed and acceleration labeling, and accurately delineate the size of the labeling frame through comprehensive shape and size information. The system is also capable of accurately dividing obstacles that are in close proximity to each other in complex scenes.
- Full-stack evaluation tool chain: it includes data collection tools, sensor calibration tools, visualization tools, manual verification tools, evaluation tools, etc. The 2.1 version upgrades the data management platform and adds the scene semantic labeling function that serves every step of the evaluation process.
- Individual sensor evaluation in the multi-sensor fusion system: not only can the RS-Reference system evaluate the result of intelligent driving's perception fusion, but it can also provide targeted solutions based on the features of different types of sensors such as LiDAR, millimeter wave radar, and camera. Dedicated or customized tool modules can be developed according to customer needs for further in-depth analysis of the performance of the sensing system.
- Extended application value of the RS-Reference: includes planning and control algorithm development support, which is able to generate massive ground truth data to build simulation scenes, and can evaluate road-side perception systems.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005689/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom